{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:21:32Z","timestamp":1772119292958,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T00:00:00Z","timestamp":1733270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Colorectal Dis"],"DOI":"10.1007\/s00384-024-04767-9","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T05:38:27Z","timestamp":1733290707000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combining moderate dosage of Bevacizumab with TAS-102 provides longer progression-free time in refractory metastatic colorectal Cancer"],"prefix":"10.1007","volume":"39","author":[{"given":"Kuan-Yu","family":"Tseng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mu-Ying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Shone","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeng-Kai","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huann-Sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Ching","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Tzu","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Chi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Hsin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Chieh","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hou-Hsuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Wen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Zu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Che-Yuan","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8480-3422","authenticated-orcid":false,"given":"Hao-Wei","family":"Teng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"key":"4767_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071732","volume":"14","author":"MS Hossain","year":"2022","unstructured":"Hossain MS, Karuniawati H, Jairoun AA et al (2022) Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies. Cancers 14:1732. https:\/\/doi.org\/10.3390\/cancers14071732","journal-title":"Cancers"},{"key":"4767_CR2","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372:1909\u20131919. https:\/\/doi.org\/10.1056\/NEJMoa1414325","journal-title":"N Engl J Med"},{"key":"4767_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2017-000261","volume":"2","author":"E Van Cutsem","year":"2017","unstructured":"Van Cutsem E, Falcone A, Garcia-Carbonero R et al (2017) Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial. ESMO Open 2:e000261. https:\/\/doi.org\/10.1136\/esmoopen-2017-000261","journal-title":"ESMO Open"},{"key":"4767_CR4","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager GW, Taieb J, Fakih M et al (2023) Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med 388:1657\u20131667. https:\/\/doi.org\/10.1056\/NEJMoa2214963","journal-title":"N Engl J Med"},{"key":"4767_CR5","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1200\/JCO.2022.40.16_suppl.3559","volume":"40","author":"CG Cann","year":"2022","unstructured":"Cann CG, Cimino S, Grieb B et al (2022) Alternative biweekly dosing schedule of trifluridine-tipiracil (TAS-102) reduces rates of myelosuppression while maintaining therapeutic efficacy in patients (pts) with previously treated metastatic colorectal cancer (mCRC). Am Soc Clin Oncol 40:3559\u20133559. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.3559","journal-title":"Am Soc Clin Oncol"},{"key":"4767_CR6","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/S1470-2045(17)30425-4","volume":"18","author":"Y Kuboki","year":"2017","unstructured":"Kuboki Y, Nishina T, Shinozaki E et al (2017) TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1\/2 study. Lancet Oncol 18:1172\u20131181. https:\/\/doi.org\/10.1016\/S1470-2045(17)30425-4","journal-title":"Lancet Oncol"},{"key":"4767_CR7","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S1470-2045(19)30827-7","volume":"21","author":"P Pfeiffer","year":"2020","unstructured":"Pfeiffer P, Yilmaz M, M\u00f6ller S et al (2020) TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol 21:412\u2013420. https:\/\/doi.org\/10.1016\/S1470-2045(19)30827-7","journal-title":"Lancet Oncol"},{"key":"4767_CR8","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1186\/s12885-019-6475-6","volume":"19","author":"D Kotani","year":"2019","unstructured":"Kotani D, Kuboki Y, Horasawa S et al (2019) Retrospective cohort study of trifluridine\/tipiracil (TAS-102) plus bevacizumab versus trifluridine\/tipiracil monotherapy for metastatic colorectal cancer. BMC Cancer 19:1253. https:\/\/doi.org\/10.1186\/s12885-019-6475-6","journal-title":"BMC Cancer"},{"key":"4767_CR9","doi-asserted-by":"publisher","first-page":"e1855","DOI":"10.1634\/theoncologist.2020-0643","volume":"25","author":"H Satake","year":"2020","unstructured":"Satake H, Kato T, Oba K et al (2020) Phase Ib\/II study of biweekly TAS-102 in combination with bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study). Oncologist 25:e1855\u2013e1863. https:\/\/doi.org\/10.1634\/theoncologist.2020-0643","journal-title":"Oncologist"},{"key":"4767_CR10","doi-asserted-by":"publisher","first-page":"14612","DOI":"10.1038\/s41598-022-18871-9","volume":"12","author":"N Mart\u00ednez-Lago","year":"2022","unstructured":"Mart\u00ednez-Lago N, Chucla TC, De Castro BA et al (2022) Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine\/tipiracil plus bevacizumab in a real-world setting. Sci Rep 12:14612. https:\/\/doi.org\/10.1038\/s41598-022-18871-9","journal-title":"Sci Rep"},{"key":"4767_CR11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1186\/s12885-019-5644-y","volume":"19","author":"H Nakagawa-Senda","year":"2019","unstructured":"Nakagawa-Senda H, Hori M, Matsuda T et al (2019) Prognostic impact of tumor location in colon cancer: the monitoring of Cancer incidence in Japan (MCIJ) project. BMC Cancer 19:431. https:\/\/doi.org\/10.1186\/s12885-019-5644-y","journal-title":"BMC Cancer"},{"key":"4767_CR12","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ejca.2011.12.004","volume":"48","author":"LJ Mekenkamp","year":"2012","unstructured":"Mekenkamp LJ, Heesterbeek KJ, Koopman M et al (2012) Mucinous adenocarcinomas: poor prognosis in metastatic colorectal cancer. Eur J Cancer 48:501\u2013509. https:\/\/doi.org\/10.1016\/j.ejca.2011.12.004","journal-title":"Eur J Cancer"},{"key":"4767_CR13","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1200\/JCO.2009.23.3452","volume":"28","author":"AD Roth","year":"2010","unstructured":"Roth AD, Tejpar S, Delorenzi M et al (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60\u201300 trial. J Clin Oncol 28:466\u2013474. https:\/\/doi.org\/10.1200\/JCO.2009.23.3452","journal-title":"J Clin Oncol"},{"key":"4767_CR14","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1200\/JCO.2008.18.0786","volume":"26","author":"F Di Nicolantonio","year":"2008","unstructured":"Di Nicolantonio F, Martini M, Molinari F et al (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705\u20135712. https:\/\/doi.org\/10.1200\/JCO.2008.18.0786","journal-title":"J Clin Oncol"},{"key":"4767_CR15","doi-asserted-by":"publisher","first-page":"4137","DOI":"10.1002\/cncr.28347","volume":"119","author":"G Karagkounis","year":"2013","unstructured":"Karagkounis G, Torbenson MS, Daniel HD et al (2013) Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer 119:4137\u20134144. https:\/\/doi.org\/10.1002\/cncr.28347","journal-title":"Cancer"}],"container-title":["International Journal of Colorectal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-024-04767-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00384-024-04767-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00384-024-04767-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T14:05:05Z","timestamp":1736345105000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00384-024-04767-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4767"],"URL":"https:\/\/doi.org\/10.1007\/s00384-024-04767-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4501755\/v1","asserted-by":"object"}]},"ISSN":["1432-1262"],"issn-type":[{"value":"1432-1262","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,4]]},"assertion":[{"value":"18 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was conducted using population-based data from Taipei Veterans General Hospital, Taiwan, following the guidelines of the Declaration of Helsinki. Approval was obtained from the Ethics Committee and Institutional Review Board of Taipei Veterans General Hospital, Taiwan. Due to the retrospective nature of the study, the requirement for written informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"195"}}